Objective: To compare and evaluate the efficacy of nebulized 3% hypertonic saline (HS) and recombinant human Dnase (rhDNase) treatment for resolution of persistent atelectasis in newborns.
Study Design: Forty newborns (38 preterms) who did not respond to conventional treatment enrolled to receive either nebulized 3% HS solution (n = 20) or rhDNase (n = 20) between September 2007 and March 2008. Clinical parameters, oxygen saturation and radiological response (chest X-ray scoring) were analyzed before and after administration of 3% HS or rhDNase.
Resolution time of atelectasis did not differ between two groups after whole treatment but the percentage of atelectasis resolution after 3 days treatment were 90% (18/20) in the 3%HS group and 70% (14/20) in the rhDNase group. The patients in the 3% HS group improved better also in clinical parameters in comparison to the rhDNase treatment. The difference of oxygen saturation before and after the treatment was 4.6 ± 0.8 in 3% HS group as in comparison to 2.6 ± 0.1 in the rhDNase group (p <>
Interesting findings!
No comments:
Post a Comment